GENE ONLINE|News &
Opinion
Blog

2020-02-06| Asia-PacificR&D

Eisai Partners with PGDx To Develop Liquid Biopsy NGS Tool Against Cancer

by GeneOnline
Share To

The non availability of patient tissue samples or the challenges that exists in obtaining them impedes data inference from clinical trials. In contrast, NGS analysis of patient blood samples provide researchers a deep insight on the cancer they are dealing with and aids in novel drug development and treatment.

Japanese Pharma Eisai Co., Ltd. has recently launched a partnership with Maryland-based Personal Genome Diagnostics Inc. (PGDx) to develop a cancer gene panel test that detects circulating tumor DNA (ctDNA) in the blood and facilitates biomarker discovery. The collaboration intends to build a liquid biopsy-based NGS kit that enables researchers to perform comprehensive genomic profiling without resorting to invasive methods.

With the automated NGS workflow, researchers could detect several genomic alterations in over 500+ cancer and drug-resistance related genes. The assay will reveal several somatic alterations including indels, copy number variations (CNVs), rearrangements, single nucleotide variants (SNVs) and genomic signatures such as microsatellite instability (MSI) and tumor mutation burden (TMB). These data will be crucial for researchers to evaluate drug response dynamics and explore the mechanisms of acquired drug resistance in tumors. The companies are committed to inviting participation from external researchers across the world while developing the kit. Both parties envision their product to offer a better solution in addressing clinical trial difficulties and become a benchmark.

“Partnering with PGDx to develop this solution is part of our Data-Driven Drug Discovery & Development (5D drug discovery) initiative to accelerate drug discovery,” said Dr. Takashi Owa, Vice President, Chief Medicine Creation and Chief Discovery Officer, Oncology Business Group at Eisai. “Utilizing digital technology, our history in drug development and PGDx’s liquid biopsy expertise, we expect this new solution will help address the complexities of developing new oncology drugs.”

References

  1. https://www.personalgenome.com/assets/resources/PGDx_Eisai_Press_Release_1.15.2020.pdf
  2. https://www.eisai.co.jp/news/2020/news202006.html

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
The Latest Talk in Cancer Immunotherapy: A Brief Overview of Developments & Current Players in the Exosome Space
2025-04-23
From Cancer to Cosmetics, Physiological to Pathological – The Field of Exosomes Full of Endless Opportunities
2025-04-22
Leqembi Makes History as First EU-Approved Drug to Target Root Cause of Alzheimer’s Disease
2025-04-15
LATEST
World Vaccine Congress Washington 2025 Recap: Urgent Calls for Trust, Tech, and Global Access
2025-04-25
Astellas’ Transformation Journey: From Merger to Global Player, Betting on the Edge of Innovation and Risk?
2025-04-25
Roche Announces Massive 50 Billion Dollar Investment in the United States
2025-04-25
Steminent Stands Ready to Showcase Novel MSC-based Therapy for Spinocerebellar Ataxia at Global Stage
2025-04-24
Arkansas Medicaid Work Requirements Led to Coverage Loss for a Significant Number of Recipients
2025-04-24
Boehringer agrees new partnership to advance first-in-class precision cancer therapies
2025-04-24
Bristol Myers Squibb Schizophrenia Drug Fails Pivotal Test as an Add-On to Antipsychotics
2025-04-24
EVENT
2025-04-25
AACR Annual Meeting 2025
Chicago, U.S.A
2025-05-03
29th Taiwan Joint Cancer Conference 2025
Taipei, Taiwan
2025-05-05
Swiss Biotech Day 2025
Basel, Switzerland
2025-05-13
ASGCT 28th Annual Meeting 2025
New Orleans, U.S.A.
2025-05-30
ASCO Annual Meeting 2025
Chicago, U.S.A
2025-06-11
ISSCR 2025 Annual Meeting
Hong Kong
Scroll to Top